Study guide
5.3 Psychopharmacology of the Major Drug Classes
National Certified Addiction Counselor NCAC
Track your progress as you read
Finished sections get a check mark.
1 Introduction to NCAC & Addiction Counseling
0.1 NCAC Exam Structure, Eligibility, and Scoring 0.2 The 12 Core Functions & TAP 21 Addiction Counseling Competencies 0.3 Study Strategy and Exam Navigation for Addiction Counselors
2 Chapter 1: Screening, Intake, and Initial Orientation
1.1 Screening Instruments, Risk Stratification, and SBIRT Protocols 1.2 The Intake Process: Clinical and Administrative Data Collection 1.3 Client Orientation, Rights, Informed Consent, and Program Expectations 1.4 Mandated, Court-Referred, and Justice-Involved Clients
3 Chapter 2: Initial Case Management and Referral Foundations
2.1 Stages of Change (Transtheoretical Model) and Initial Engagement 2.2 Referral Coordination, Community Resources, and Interdisciplinary Linkage 2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement
4 Chapter 3: Biopsychosocial Assessment & Diagnostic Foundations
3.1 Comprehensive Biopsychosocial Assessment & The Addiction Severity Index (ASI) 3.2 DSM-5-TR Substance Use Disorders: Criteria, Specifiers, and Neurobiology of Addiction 3.3 Behavioral and Process Addictions: Assessment and Clinical Features 3.4 Models and Theories of Addiction Etiology
5 Chapter 4: Co-Occurring Disorders & Risk Assessment
4.1 Co-Occurring Mental Health Disorders & Differential Diagnosis 4.2 Suicide Risk Assessment, Self-Harm, and Crisis Safety Planning 4.3 Trauma-Informed Assessment, PTSD, and Adverse Childhood Experiences (ACEs)
6 Chapter 5: Medical, Toxicology, and Special Population Considerations
5.1 Medical Evaluation, Toxicology Screening, and Infectious Disease Risks 5.2 Cultural, Developmental, and Special Population Assessment Adaptations 5.3 Psychopharmacology of the Major Drug Classes 5.4 Physiological Effects of Substance Use Across Body Systems
7 Chapter 6: The ASAM Criteria & Level of Care Placement
6.1 The ASAM Criteria: The Six Multidimensional Assessment Dimensions 6.2 ASAM Continuum of Care: Levels 0.5 Through 4.0 6.3 Placement Matching, Continued Service, Transfer, and Discharge Criteria
8 Chapter 7: Individualized Treatment Planning & Pharmacotherapy
7.1 Developing Measurable, Individualized Treatment Plans (SMART Objectives) 7.2 Medications for Addiction Treatment (MAT/MOUD) and Pharmacotherapies 7.3 Monitoring Clinical Progress, Plan Review, and Interdisciplinary Care
9 Chapter 8: Case Management, Relapse Prevention & Continuing Care
8.1 Case Management Models, Advocacy, and Resource Coordination 8.2 Relapse Dynamics, Warning Signs, and Relapse Prevention Models 8.3 Continuing Care, Recovery Capital, and Peer Support Systems 8.4 Clinical Documentation, Progress Notes, and the Golden Thread 8.5 Outcome Measurement, Program Evaluation, and Evidence-Based Practice
10 Chapter 9: Core Counseling Modalities & Individual Skills
9.1 Motivational Interviewing: Spirit, Principles, OARS, and Change Talk 9.2 Cognitive Behavioral Therapy (CBT) & REBT in Addiction Treatment 9.3 Additional Evidence-Based Approaches: SFBT, Contingency Management, and Mindfulness 9.4 Mutual-Help Programs, Twelve-Step Facilitation, and Recovery Support
11 Chapter 10: Group Dynamics & Family Systems
10.1 Group Counseling Dynamics, Types of Groups, and Yalom's Therapeutic Factors 10.2 Group Leadership Skills, Managing Challenging Behaviors, and Developmental Stages 10.3 Family Systems Theory, Roles, Codependency, and Family Interventions
12 Chapter 11: Crisis Intervention & Psychoeducation
11.1 Crisis Intervention Models, De-escalation Techniques, and Overdose Response 11.2 Psychoeducation, Health Literacy, and Client Self-Advocacy
13 Chapter 12: Legal Standards, Confidentiality & 42 CFR Part 2
12.1 Federal Confidentiality Regulations: 42 CFR Part 2 and HIPAA Integration 12.2 Duty to Warn / Protect (Tarasoff) and Mandated Reporting Laws 12.3 Legal Issues, Subpoenas, Court Mandates, and Clinical Record Retention 12.4 Confidentiality with Minors, Groups, Families, and Collaterals
14 Chapter 13: NAADAC Ethics, Cultural Humility & Supervision
13.1 The NAADAC Code of Ethics: Core Principles, Boundaries, and Dual Relationships 13.2 Cultural Humility, Implicit Bias, and Culturally Responsive Care 13.3 Clinical Supervision, Professional Impairment, Compassion Fatigue, and Self-Care 13.4 Technology in Practice: Telehealth, E-Supervision, AI, and Social Media 13.5 Professional Development, Credentialing, and Scope of Practice
5.3 Psychopharmacology of the Major Drug Classes
Key Takeaways Explain This Topic AI
Physiology and psychopharmacology is one of the nine skill groups NCC AP names for its examinations, so drug classification, intoxication and withdrawal profiles, and the mechanics of tolerance are directly testable content.
Withdrawal from alcohol and other CNS depressants can be fatal through seizures and delirium tremens, whereas opioid withdrawal is intensely uncomfortable but rarely lethal in otherwise healthy adults — a distinction that drives triage decisions.
Route of administration governs onset and abuse liability: intravenous and inhaled routes reach the brain in seconds, while oral routes take 20 to 60 minutes, which is why the same drug carries different risk profiles by route.
Cross-tolerance within a pharmacological class is what allows one drug to substitute for another during withdrawal management, such as a long-acting benzodiazepine for alcohol.
Half-life predicts withdrawal timing: short-half-life drugs produce early, intense withdrawal, while long-half-life drugs produce delayed, prolonged withdrawal, which is why alprazolam and methadone withdrawal follow very different clocks.
Last updated: August 2026
5.3 Psychopharmacology of the Major Drug Classes
NCC AP names physiology and psychopharmacology as one of the nine skill groups its examinations evaluate, and NAADAC's own preparation guidance directs candidates to pharmacology webinars and to the Basics of Addiction module devoted to it. Counselors are not prescribers, but they are expected to recognize what a client is intoxicated on, know which withdrawal syndromes can kill, and understand why the same substance behaves differently when it is smoked rather than swallowed.
This section is organized by pharmacological class, because class membership — not street name or legal schedule — predicts intoxication signs, withdrawal risk, cross-tolerance, and dangerous combinations.
1. The Major Pharmacological Classes
Class Representative Substances Primary Mechanism Intoxication Presentation Withdrawal Presentation Withdrawal Danger
CNS Depressants (sedative-hypnotics) Alcohol, benzodiazepines, barbiturates, GHB, "Z-drugs" Enhance inhibitory GABA-A transmission; alcohol also inhibits NMDA glutamate Slurred speech, ataxia, disinhibition, nystagmus, impaired memory, sedation, respiratory depression at high dose Autonomic hyperactivity, tremor, insomnia, anxiety, nausea, hallucinations, seizures, delirium POTENTIALLY FATAL — seizures and delirium tremens; requires medical withdrawal management
Opioids Heroin, fentanyl, morphine, oxycodone, hydrocodone, methadone, buprenorphine Mu-opioid receptor agonism Euphoria then sedation, pinpoint pupils , itching, constipation, slowed respiration, "nodding" Dilated pupils, lacrimation, rhinorrhea, yawning, piloerection, myalgia, abdominal cramping, diarrhea, vomiting, intense craving Rarely fatal in healthy adults, but dangerous with dehydration, in pregnancy, and because of overdose risk after tolerance loss
Stimulants Cocaine, methamphetamine, amphetamine salts, methylphenidate, cathinones Increase synaptic dopamine and norepinephrine (reuptake blockade or reversal of transport) Euphoria, hypervigilance, grandiosity, pressured speech, dilated pupils, tachycardia, hypertension, hyperthermia, paranoia, formication "Crash": profound dysphoria, hypersomnia, hyperphagia, psychomotor slowing, vivid dysphoric dreams, intense craving, suicidal ideation Not physiologically lethal, but the depressive crash carries real suicide risk requiring assessment
Cannabinoids Cannabis, concentrates, synthetic cannabinoids ("K2," "Spice") CB1 receptor agonism (synthetics are full agonists and far more potent) Conjunctival injection, increased appetite, tachycardia, altered time perception, impaired short-term memory, anxiety or paranoia at high potency Irritability, anger, anxiety, sleep disturbance with vivid dreams, decreased appetite, restlessness, physical discomfort (a DSM-5 diagnosis) Not dangerous, but frequently underestimated by clients and clinicians; synthetic cannabinoids can cause seizures, agitation, and death
Hallucinogens LSD, psilocybin, mescaline, DMT Primarily 5-HT2A serotonin agonism Perceptual distortion with generally intact reality testing, synesthesia, dilated pupils, emotional lability, possible panic No characteristic physiological withdrawal syndrome Risk is behavioral — panic reaction, injury, hallucinogen persisting perception disorder
Dissociatives PCP, ketamine, dextromethorphan, nitrous oxide NMDA receptor antagonism Nystagmus (classically vertical with PCP), dissociation, analgesia, agitation, unpredictable violence, ataxia, blank stare Mild; craving and dysphoria Behavioral danger during intoxication is the primary risk; nitrous causes B12 inactivation and neuropathy
Inhalants Toluene-based solvents, glue, paint thinner, aerosols, nitrites Varied, largely nonspecific membrane and GABA effects Rapid brief intoxication, dizziness, slurred speech, euphoria, chemical odor, perioral rash ("glue sniffer's rash") Mild and inconsistent Sudden sniffing death syndrome from cardiac arrhythmia can occur on any exposure, including the first
Nicotine Cigarettes, vaping products, smokeless tobacco Nicotinic acetylcholine receptor agonism Mild stimulation, appetite suppression Irritability, anxiety, difficulty concentrating, increased appetite, craving, dysphoria Not dangerous, but the leading preventable cause of death among people in SUD treatment
Anabolic-androgenic steroids Testosterone esters, nandrolone, stanozolol Androgen receptor agonism Not classically euphoric; irritability, aggression, mood lability Depression, fatigue, loss of libido; depression can be severe Withdrawal depression carries suicide risk
Important
The rule that decides triage. Ask first: is this a CNS depressant? Withdrawal from alcohol, benzodiazepines, and barbiturates can kill through seizures and delirium tremens and requires medical management. Opioid withdrawal feels catastrophic to the client and looks dramatic, but is rarely lethal in a healthy adult. Candidates who reverse these two facts choose the wrong level of care on vignette items — and, in practice, send the wrong person home.
2. Route, Onset, and Abuse Liability
The faster a drug reaches the brain, the more intense the reinforcement and the higher the abuse liability. The same molecule can be a moderate-risk medication by one route and a high-risk drug by another.
Route Approximate Time to CNS Effect Notes
Intravenous 5 to 20 seconds Highest abuse liability; infection, endocarditis, abscess, and bloodborne virus risk
Inhalation / smoking 7 to 10 seconds Effectively as fast as IV; drives crack cocaine and methamphetamine use patterns; pulmonary damage
- Intranasal (snorting) 3 to 5 minutes Nasal septum damage with chronic use
- Sublingual / buccal 5 to 15 minutes Bypasses first-pass metabolism; the buprenorphine route
- Oral 20 to 60 minutes Slowest onset, lowest abuse liability, subject to first-pass hepatic metabolism
- Transdermal Hours Fentanyl patches; diversion by chewing or extraction is a well-known lethal risk
- 3. Half-Life, Potency, and the Shape of Withdrawal
Half-life is the time for plasma concentration to fall by half, and it sets the clock for withdrawal:
Short half-life leads to early, intense withdrawal. Alprazolam, heroin, and short-acting alcohol effects produce withdrawal within hours, sharply peaked.
Long half-life leads to delayed, prolonged, milder-per-day withdrawal. Diazepam, methadone, and chlordiazepoxide produce withdrawal that may not begin for one to three days and can last weeks.
This is why withdrawal management often substitutes a long-acting agent within the same class — chlordiazepoxide or diazepam for alcohol, methadone or buprenorphine for short-acting opioids — and then tapers it. The substitution works because of cross-tolerance.
Rough withdrawal timelines to know:
Substance Onset Peak Duration
Alcohol 6 to 24 hours 24 to 72 hours (seizure risk 12 to 48 hours; delirium tremens typically 48 to 96 hours) 5 to 7 days for acute phase
- Short-acting opioids (heroin) 8 to 12 hours 36 to 72 hours 4 to 7 days
- Methadone 24 to 48 hours 3 to 8 days 2 to 3 weeks or longer
- Short-acting benzodiazepines 1 to 2 days 2 to 4 days 2 to 4 weeks, with protracted symptoms possible
- Long-acting benzodiazepines 2 to 7 days 1 to 2 weeks Weeks to months
- Stimulants Hours 2 to 4 days 1 to 2 weeks of anhedonia and craving
Post-acute withdrawal. After the acute syndrome resolves, many clients experience weeks to months of sleep disturbance, mood instability, cognitive fog, and craving surges. Normalizing this — and warning the client it is coming — prevents the interpretation "the treatment isn't working" that so often precedes a return to use.
4. Tolerance and Its Relatives
Term Definition Clinical Illustration
Tolerance Diminished response to the same dose, or the need for more to achieve the same effect A DSM-5-TR criterion; the client who now needs a fifth of vodka to feel what a pint once produced
Metabolic (pharmacokinetic) tolerance Liver enzyme induction speeds drug clearance Chronic alcohol use inducing CYP2E1
Cellular (pharmacodynamic) tolerance Receptor downregulation and adaptation Mu-opioid receptor adaptation
Behavioral tolerance Learned compensation for impairment The experienced drinker who can walk a straight line at a blood alcohol level that would floor a novice
Acute tolerance (tachyphylaxis) Tolerance developing within a single episode of use Greater impairment on the ascending than the descending limb of the blood alcohol curve
Reverse tolerance (sensitization) Increased response to the same dose over time Stimulant-induced psychosis emerging at doses previously tolerated; advanced liver disease lowering alcohol tolerance
Cross-tolerance Tolerance to one drug conferring tolerance to another in the same class Why a benzodiazepine can substitute for alcohol in withdrawal management
Cross-dependence One drug can suppress withdrawal from another in the same class The pharmacological basis of methadone and buprenorphine maintenance
Drug interactions that kill:
Additive / synergistic depression. Alcohol plus benzodiazepines plus opioids — all three depress respiration, and combinations account for a large share of overdose deaths. The opioid-plus-benzodiazepine combination is the one most often tested.
Potentiation. One drug amplifies another's effect beyond simple addition.
Antagonism. One drug blocks another — the therapeutic mechanism of naloxone and naltrexone, and the reason naltrexone precipitates violent withdrawal in an opioid-dependent person.
Speedball patterns. Combining a stimulant with an opioid masks the sedative warning signs of opioid overdose while the stimulant wears off first, leaving unopposed respiratory depression.
Note
Counselor scope. Recognizing these patterns is squarely within a counselor's role; adjusting medications is not. The correct action on an examination item is to report objective observations to the medical team or refer for medical evaluation , not to advise the client about dosing. See Section 13.5 on scope of practice.